GALECTIN THERAPEUTICS INC — Director's Dealing 2022

Jan 25, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2022-01-24

Reporting Person: Boudes Pol F (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-24	Stock Option (right to buy)	$1.98	A	50000	Acquired	2032-01-24	Common Stock (50000)	Direct

Footnotes

F1: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F2: The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023.